News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2025 Caitlin E. Cox July 31, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News CVD Hospitalization in Older Adults Higher in US Than in Denmark Michael O'Riordan February 07, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Daily News Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates L.A. McKeown January 10, 2025
News Daily News GLP-1 Receptor Agonists Come With Broad Array of Benefits, Risks Todd Neale January 21, 2024